ReviewFrontiers in pharmacology2026
The Tibetan Medicinal Formula Ruyi Zhenbao: Research progress on pharmacological actions, clinical evidence and compatibility.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To comprehensively review the research progress on the compatibility principles, pharmacological mechanisms, and clinical evidence of the Tibetan medicinal formula Ruyi Zhenbao. Methods: Guided by fundamental Tibetan medical theory, a critical review of domestic and international literature was conducted, systematically integrating Tibetan medicinal compatibility theory, preclinical pharmacological evidence, and clinical research data. Results: Based on the multi-level medicinal property compatibility structure of Tibetan medicine, this formula combines 30 medicinal materials according to their properties and effects, forming a synergistic therapeutic system with heat-clearing, mind-awakening, collateral-dredging, and serous-fluid-drying properties. Preclinical studies indicate that Ruyi Zhenbao Formula may exert integrative regulatory effects through multiple targets and pathways, demonstrating multiple pharmacological activities including neuroprotection and repair, anti-inflammatory and immunomodulation, multi-mechanism synergistic analgesia, and microcirculation improvement. Clinical evidence suggests that this formula demonstrates potential efficacy in conditions such as osteoarthritis, cerebrovascular diseases, and neurological disorders, with acceptable safety profiles based on available data. Conclusion: Current preclinical and clinical evidence supports the traditional applications of the Ruyi Zhenbao Formula and provides preliminary scientific insights into the Tibetan medical theories underlying its use. This review contributes to understanding the potential of integrating traditional Tibetan medical knowledge with modern biomedical research. However, a ConPhyMP-based quality assessment showed that none of the included primary studies reported voucher specimens or chemical fingerprints, underscoring the need for standardized phytochemical characterization in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.